Abstract: Objective To explore the effects of methylprednisolone combined with triamcinolone acetonide on thyroid-associated ophthalmopathy (TAO) and Ocular Surface Disease Index (OSDI) and Clinical Activity Score (CAS). Methods A total of 60 patients (120 eyes) with TAO were divided into two groups according to random number table: observation group and control group (30 cases and 60 eyes in each group). Patients in the control group were treated with methylprednisolone, while patients in the observation group were treated with triamcinolone acetonide on the basis of the control group. The clinical efficacy and adverse reactions were compared between the two groups after treatment. The exophthalmos, width of palpebral fissure, CAS score and OSDI score before and after treatment were detected and compared between the two groups. Results There was no significant difference in the degree of exophthalmos and the width of palpebral fissure between the two groups before treatment (P>0.05). After treatment, the degree of exophthalmos and the width of palpebral fissure were significantly improved in both groups (P<0.01). Compared with the control group, the improvement of the degree of exophthalmos and the width of palpebral fissure in the observation group was more obvious (P<0.01). There was no significant difference in CAS score and OSDI score between the two groups before treatment (P>0.05). After treatment, CAS score and OSDI score in both groups decreased significantly (P<0.05), especially in the observation group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusions The combination of methylprednisolone and triamcinolone acetonide has better clinical efficacy in TAO patients. It can significantly reduce inflammation, improve CAS score and OSDI score, and have better prognosis.